Dr Shadman discusses an indirect comparison evaluating zanubrutinib vs acalabrutinib plus venetoclax in chronic lymphocytic leukemia.
Back
Assessing Zanubrutinib vs Acalabrutinib Plus Venetoclax in Frontline CLL
Assessing Zanubrutinib vs Acalabrutinib Plus Venetoclax in Frontline CLL
Episodes
All
All
In a post hoc indirect comparison, data showed zanubrutinib was linked to improved PFS vs acalabrutinib/venetoclax in patients with treatment-naive CLL.
Mazyar Shadman, MD, MPH, discusses a post hoc analysis that compared data BTK inhibitor–based regimens for treatment-naive chronic lymphocytic leukemia.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
The OncFive: Top Oncology Articles for the Week of 8/30
5